Urinary Tract Infections — Uncomplicated and Complicated

Bacterial Adherence and Colonization Mechanisms

• Fimbrial adhesins and type 1 pili: Uropathogenic Escherichia coli (UPEC) possess P fimbriae (pili) that specifically bind to α-D-galactopyranosyl-(1→4)-β-D-galactose (Gal-Gal) epitopes on uroplakin Ia and uroplakin Ib in the urothelium, enabling initial adherence. Type 1 pili mediate binding to D-mannose receptors. This adherence is the rate-limiting step preventing bacterial washout by normal urine flow (approximately 100-200 mL/min in the bladder)
• Flagellar motility and chemotaxis: Bacterial flagella enable directed movement toward the urinary epithelium through chemotaxis toward chemical gradients (glucose, amino acids, uric acid). Non-motile mutants fail to establish infection even with high bacterial inocula
• Biofilm formation: Adherent bacteria upregulate polysaccharide capsule synthesis and extracellular polymeric substance (EPS) production, creating biofilms that resist antibiotic penetration and immune clearance. Biofilms achieve antibiotic concentrations 100-1000-fold lower than planktonic bacteria

Host Urinary Tract Defense Mechanisms

• Urine flow dynamics and dilution: Unobstructed urine flow continuously mechanically eliminates bacteria (the "washout effect"). Normal bladder capacity is 400-500 mL, creating pressure gradients that facilitate bacterial clearance. Vesicoureteral reflux (VUR), obstruction, and post-void residual urine each compromise this critical defense
• Urine antimicrobial properties: Urea (120-200 mM) and hydrogen ion concentration (urine pH 4.5-8.0) create an inhospitable environment. Uromucoid (Tamm-Horsfall protein/uroplakin) binds type 1 pili in solution, preventing bacterial adherence. Lactoferrin and lysozyme possess direct antimicrobial activity
• Epithelial barrier function and innate immunity: The urothelium comprises specialized umbrella cells connected by tight junctions (occludin, claudins, ZO-1 proteins) creating an impermeable barrier. Glycosaminoglycans (GAGs), particularly chondroitin sulfate and heparin sulfate, coat the urothelial surface and function as a "molecular sieve" preventing bacterial adhesion. Upon bacterial invasion, epithelial cells secrete IL-6, IL-8, and TNF-α, recruiting neutrophils and promoting polymorphonuclear leukocyte (PMN) infiltration within 4-6 hours

Epithelial Cell Invasion and Intracellular Bacterial Communities

• Bacterial lipopolysaccharide (LPS) signaling: UPEC LPS activates TLR4 on epithelial cells, triggering rapid MAPK and NF-κB signaling cascades. This initiates zipper-mediated endocytosis of bacteria into membrane-bound vesicles
• Intracellular bacterial communities (IBCs) formation: Internalized bacteria establish IBCs—organized, sessile biofilm-like aggregates within epithelial cells—containing hundreds to thousands of bacteria in a glycoprotein-rich matrix. IBCs are protected from antibiotics and immune attack, representing a potential reservoir for recurrent UTI. Formation involves upregulation of ftsZ (bacterial cell division protein) and polysaccharide synthesis operons
• Filamentous persistence: Some bacteria enter a viable but non-culturable state or form filamentous forms (10-300 μm length) that evade immune recognition, enabling chronic infection and recurrence

Host Genetic Factors and Susceptibility

• Uroplakin polymorphisms: Variations in uroplakin genes affect pili binding density and epithelial vulnerability. Women homozygous for certain ABO blood group antigens (non-secretors) lack protective soluble ABO antigens in urine and saliva
• Inflammatory response variations: Polymorphisms in IL-1β, IL-6, and TNF-α genes modify cytokine response magnitude, affecting both symptom severity and bacterial clearance efficiency
• Estrogen-dependent mechanisms: Estrogen regulates glycogen content in vaginal epithelium and vaginal flora composition, affecting periurethral colonization by uropathogens

Primary Microbial Causes

• Uropathogenic Escherichia coli (UPEC): Accounts for 80-85% of uncomplicated cystitis and 50-60% of pyelonephritis cases. UPEC strains possess virulence factors (P fimbriae, type 1 pili, hemolysin, aerobactin iron-acquisition systems, usp genes) conferring urinary tract tropism. Higher prevalence in women reflects increased fecal-to-periurethral bacterial transmission with sexual activity
• Staphylococcus saprophyticus: Causes 5-15% of uncomplicated cystitis in young women, particularly in sexually active females aged 15-24 years. Possesses hemagglutinin and lipoteichoic acid enabling urinary epithelial adherence. Characteristically coagulase-negative but distinct from S. epidermidis
• Klebsiella pneumoniae: Causes 3-5% of community-acquired UTIs, more common in diabetic and elderly populations. Possesses capsular polysaccharides and enterobactin iron-acquisition systems
• Proteus mirabilis: Accounts for 3-5% of uncomplicated UTIs, more prevalent in complicated infections. Produces urease, hydrolyzing urea to ammonia and elevating urine pH, promoting struvite stone formation. Associated with chronic Foley catheterization
• Pseudomonas aeruginosa: Occurs in 1-2% of community-acquired UTIs but in 20-30% of catheterized patients. Possesses multiple antibiotic resistance mechanisms (β-lactamase, aminoglycoside-modifying enzymes, reduced membrane permeability)

Non-Bacterial Pathogens

• Candida albicans: Causes 1-3% of community-acquired UTIs; more prevalent with prolonged antibiotic use (disrupting normal flora), indwelling catheters, and diabetes mellitus
• Adenovirus serotypes 40 and 41: Cause viral hemorrhagic cystitis (particularly in immunocompromised hosts); BK polyomavirus causes hemorrhagic cystitis in renal transplant recipients

Risk Factors for Uncomplicated UTI

• Female sex and anatomic factors: Women have a 50-fold higher lifetime UTI incidence than men due to shorter urethra (4 cm vs. 15-16 cm), increased periurethral bacterial colonization, and proximity of urethral meatus to anus. Urethral pressure profiles are lower in women, facilitating bacterial ascension
• Sexual activity and spermicide use: Each act of sexual intercourse increases UTI risk 60-fold within 24-48 hours through mechanical introduction of bacteria into the bladder. Spermicide-coated condoms and diaphragm use alter vaginal flora pH and disrupt normal lactobacilli, promoting uropathogen colonization
• Pregnancy: UTI prevalence increases from 2% to 5-10% during pregnancy due to progesterone-induced ureteral dilation, reduced ureteral peristalsis, and increased urinary stasis. Asymptomatic bacteriuria occurs in 2-10% of pregnant women and requires treatment due to 20-40% progression risk to acute pyelonephritis (which carries increased preterm labor and infant mortality risk)
• Contraceptive use: Oral contraceptives slightly increase UTI risk through effects on vaginal flora; intrauterine devices (IUDs) increase risk through persistent inflammation
• Post-menopausal status: Estrogen deficiency reduces vaginal lactobacillus predominance, promoting uropathogen colonization. Vaginal atrophy increases epithelial fragility

Risk Factors for Complicated UTI

• Functional or structural urinary tract abnormalities: Vesicoureteral reflux (VUR), urinary obstruction (stones, tumors, strictures), neurogenic bladder (spinal cord injury, diabetic neuropathy), benign prostatic hyperplasia (BPH), and ureteropelvic junction obstruction create urinary stasis, enabling bacterial proliferation
• Indwelling catheters: Foley catheterization increases UTI risk 3-7% per day of catheterization. Biofilms develop on catheter surfaces within 24-48 hours; catheter-associated UTI (CAUTI) affects 15-25% of hospitalized patients with catheters
• Immunocompromised states: HIV/AIDS (CD4 <200), solid organ or bone marrow transplantation, active chemotherapy, and systemic corticosteroid use increase both UTI incidence and severity. Polymorphonuclear leukocyte dysfunction impairs bacterial clearance
• Diabetes mellitus: Causes 1.5-3 fold increased UTI risk through hyperglycemia-induced glycosuria (enhancing bacterial growth), neutrophil dysfunction, and increased asymptomatic bacteriuria
• Male sex: Any UTI in a man is considered complicated. Prostate gland secretions possess zinc, magnesium, and lysozyme with antimicrobial properties; infection may reflect prostatitis, benign prostatic hyperplasia with retention, or anatomic abnormality
• Chronic kidney disease: Reduced GFR and uremia impair leukocyte function and increase asymptomatic bacteriuria prevalence

Uncomplicated Cystitis (Lower UTI)

• Dysuria: Sharp, burning pain during micturition localized to the urethra and bladder occurring in 50-90% of cases. Results from epithelial mucosal inflammation and release of bradykinin and prostaglandins. Typically occurs at initiation and termination of voiding
• Frequency and urgency: Polyuria (>8 voids daily) and nocturia occur due to inflammatory-induced lowering of the sensory threshold for bladder stretch receptors. Urgency reflects detrusor instability and hyperreflexia induced by bacterial antigens
• Suprapubic discomfort: Mild to moderate suprapubic pain and pressure sensation results from bladder wall inflammation and distension. Pain worsens with bladder filling, improves with emptying
• Hematuria: Gross or microscopic hematuria occurs in 40-60% of cases secondary to mucosal ulceration and capillary rupture within inflamed urothelium. "Cola-colored" urine suggests significant bleeding
• Absence of systemic symptoms: Fever, malaise, flank pain, and costovertebral angle (CVA) tenderness are absent, distinguishing uncomplicated cystitis from pyelonephritis. Normal vital signs and general appearance
• Laboratory urinalysis findings: Pyuria (>5 WBC/hpf or positive leukocyte esterase) reflects PMN infiltration; bacteriuria (>10⁵ CFU/mL) indicates bacterial proliferation

Acute Pyelonephritis (Upper UTI)

• Fever and systemic toxicity: High fever (often >38.5°C/101.3°F), chills, rigors, and malaise result from bacterial endotoxin (LPS) release triggering IL-1, IL-6, and TNF-α release, resetting the hypothalamic set point. Timing: fever typically develops over 6-24 hours
• Costovertebral angle (CVA) tenderness: Unilateral or bilateral flank pain with percussion tenderness over CVA occurs in 80-90% of pyelonephritis cases, reflecting kidney capsule distension and interstitial inflammation. Reproducible by CVA punch tenderness
• Lower urinary tract symptoms: Dysuria, frequency, and urgency may persist or be absent; when present, they often precede systemic symptoms by 1-3 days
• Nausea, vomiting, and abdominal pain: Occur in 50-60% of cases, sometimes overshadowing urinary symptoms. Reflects visceral innervation of kidney via sympathetic splanchnic nerves and peritoneal irritation from retroperitoneal inflammation
• Sepsis manifestations: Severe pyelonephritis progresses to urosepsis with hypotension (SBP <90 mmHg), tachycardia (>90 bpm), tachypnea (>20 breaths/min), and altered mental status. Occurs in 15-20% of hospitalized pyelonephritis patients

Asymptomatic Bacteriuria

• Definition: Bacteriuria without symptoms (≥10⁵ CFU/mL in midstream urine). Occurs in 1-3% of non-pregnant women, 3-10% of pregnant women, 15-20% of diabetics, and 20-50% of elderly persons
• Clinical significance: Generally benign and self-limited in non-pregnant women and children; requires treatment only in pregnancy and prior to urologic procedures. Most cases resolve spontaneously within 1 year

Atypical/Complicated UTI Presentations

• Male UTI with prostatitis: Presents with dysuria, frequency, urgency, but also perineal pain, pain with defecation, and erectile dysfunction. Digital rectal exam (DRE) reveals boggy, tender prostate. Risk of bacteremia and sepsis higher than in women
• Catheter-associated UTI (CAUTI): Often asymptomatic despite significant bacteriuria. When symptomatic: fever, altered mental status (in elderly), catheter obstruction, or hematuria. Symptoms often more subtle than in non-catheterized patients
• Spinal cord injury and neurogenic bladder: Patients may lack typical pain symptoms due to sensory impairment. Present with fever alone, autonomic dysreflexia (sudden hypertension, bradycardia, headache), or signs of sepsis
• Elderly persons: Often present with atypical symptoms: acute mental status changes, falls, functional decline, absence of fever (due to blunted inflammatory response). Dysuria and frequency may be absent, delaying diagnosis

Physical Examination Findings

• **Suprapubic tenderness to palpation

Step 2 — Urinalysis (initial test)

• Leukocyte esterase: released by neutrophil azurophilic granules; a surrogate for pyuria, sensitive but not specific (positive in urethritis, nephrolithiasis, interstitial nephritis).
• Nitrite: Enterobacterales reduce dietary nitrate to nitrite — highly specific, poorly sensitive. False negatives with Staphylococcus saprophyticus, Enterococcus, and Pseudomonas (non-nitrate-reducers) and with short bladder dwell time.
• Microscopy: pyuria (conventionally ≥10 WBC/hpf on uncentrifuged urine) plus bacteriuria. WBC casts localize infection to the renal parenchyma and are the classic finding of pyelonephritis. Sterile pyuria points to Chlamydia trachomatis urethritis, renal tuberculosis, or interstitial nephritis.

Step 3 — Urine culture (gold standard)

• Thresholds: ≥10⁵ CFU/mL in a clean-catch midstream specimen is the classic cut-off, but ≥10² CFU/mL of a uropathogen in a symptomatic woman is diagnostic; IDSA uses ≥10³ CFU/mL from a catheterized specimen for CAUTI.
• When to culture: pyelonephritis, all complicated UTI, men, pregnancy, recurrence, treatment failure, and healthcare-associated infection. Culture is not required for a first episode of uncomplicated cystitis.
• Asymptomatic bacteriuria (IDSA 2019): two consecutive voided specimens in women, one in men, at ≥10⁵ CFU/mL, without symptoms.

Uncomplicated cystitis — first-line (IDSA/ESCMID)

• Nitrofurantoin (monohydrate/macrocrystals) for 5 days: concentrates in urine but not renal parenchyma.
• TMP-SMX for 3 days: avoid if local E. coli resistance exceeds ~20% or if used in the prior 3–6 months.
• Fosfomycin trometamol: single 3 g oral dose; convenient but modestly less effective.

Pyelonephritis

• Outpatient: oral fluoroquinolone (ciprofloxacin) for 7 days if local resistance is low; if resistance is higher or a fluoroquinolone is unsuitable, give an initial long-acting parenteral dose (ceftriaxone 1 g IV or an aminoglycoside) then oral therapy. TMP-SMX requires 14 days and susceptibility confirmation.
• Inpatient: IV third-generation cephalosporin; escalate to piperacillin-tazobactam or a carbapenem (meropenem) when ESBL risk factors, recent hospitalization, or prior resistant isolates are present. Narrow on culture.

Contraindicated / avoid

• Nitrofurantoin and fosfomycin in pyelonephritis or prostatitis — inadequate tissue levels; nitrofurantoin is also avoided in significant renal impairment.
• Fluoroquinolones and TMP-SMX in pregnancy; ACOG/USPSTF support screening and treating asymptomatic bacteriuria in pregnancy with a beta-lactam, nitrofurantoin, or fosfomycin (nitrofurantoin and sulfonamides avoided near term).
• Do not treat asymptomatic bacteriuria outside pregnancy and pre-urologic procedures with anticipated mucosal bleeding (IDSA 2019).

Emergencies

• Urosepsis / septic shock: endotoxin-driven cytokine release causes vasoplegia; signalled by hypotension, lactate elevation, and altered mentation. Highest risk in men, the obstructed, and the catheterized.
• Obstructive pyonephrosis: pus under pressure behind a stone or stricture; fever persisting beyond 48–72 hours of appropriate antibiotics with hydronephrosis on imaging. Requires emergent decompression, not more antibiotics.
• Emphysematous pyelonephritis: gas-forming necrotizing infection, almost always in poorly controlled diabetes; E. coli and Klebsiella ferment glucose to CO₂. Gas within the renal parenchyma on CT is diagnostic.
• Renal or perinephric abscess: loculated infection seeding from parenchymal microabscesses or hematogenously (S. aureus); persistent fever with a flank mass or point tenderness.

Subacute and chronic

• Papillary necrosis: ischemic sloughing of medullary papillae; suspect with diabetes, sickle cell disease, analgesic nephropathy, or obstruction. Gross hematuria with passage of tissue and a ring shadow on urography.
• Chronic pyelonephritis / reflux nephropathy: repeated upper-tract infection with vesicoureteral reflux produces coarse cortical scars with blunted calyces and thyroidization of tubules; leads to hypertension and CKD.
• Xanthogranulomatous pyelonephritis: chronic Proteus infection with staghorn calculi; lipid-laden foamy macrophages and the bear-paw CT appearance; often needs nephrectomy.
• Struvite (magnesium ammonium phosphate) stones: urease-splitting organisms alkalinize urine; require complete stone removal to cure.
• Pregnancy: pyelonephritis carries risk of preterm labor, low birth weight, and ARDS from endotoxin-mediated capillary leak.

Treatment-related

• TMP-SMX: hyperkalemia (ENaC blockade), a creatinine rise without true GFR loss (blocks tubular creatinine secretion), rash and Stevens-Johnson syndrome, folate antagonism.
• Nitrofurantoin: hemolysis in G6PD deficiency, acute pneumonitis or chronic pulmonary fibrosis, peripheral neuropathy.
• Fluoroquinolones: tendinopathy and rupture, QT prolongation, aortic aneurysm/dissection, hypoglycemia, CNS effects.
• Any agent: Clostridioides difficile colitis and selection of ESBL-producing organisms.

• **Positive nitrite means *Enterobacterales***: a negative nitrite with dysuria and pyuria in a sexually active young woman should raise Staphylococcus saprophyticus — coagulase-negative and, unlike S. epidermidis, novobiocin-resistant.
• WBC casts = pyelonephritis: casts form only in tubules, so they localize infection above the bladder. Fever plus CVA tenderness plus WBC casts is the classic triad the stem is building.
• Single best next step in a febrile UTI not improving after 48–72 hours: contrast-enhanced CT of the abdomen/pelvis to find obstruction, abscess, or gas — followed by drainage or stenting, since source control beats antibiotic escalation.
• Never use nitrofurantoin or fosfomycin for pyelonephritis or prostatitis — they achieve urinary but not tissue concentrations. This is the most common distractor on cystitis-versus-pyelonephritis questions.
• Treat asymptomatic bacteriuria only in pregnancy and before urologic procedures with expected mucosal bleeding (IDSA 2019). A positive culture in a nursing-home resident with delirium and no other findings is not automatic grounds for antibiotics — but delirium in the elderly can be the only manifestation of true infection, so look for fever, leukocytosis, or hemodynamic change.
• Any UTI in a male is complicated: obtain a culture, consider prostatitis, and avoid vigorous prostate massage in acute bacterial prostatitis (bacteremia risk). Boggy, exquisitely tender prostate on rectal exam is the giveaway.
• Urease producers: Proteus mirabilis (also Klebsiella, Staphylococcus saprophyticus) alkalinize urine → struvite staghorn calculi and xanthogranulomatous pyelonephritis.
• Pregnancy pharmacology: TMP-SMX is avoided in the first trimester (folate antagonism/neural tube defects) and at term (kernicterus); nitrofurantoin is avoided near term (neonatal hemolysis); fluoroquinolones are avoided throughout. Cephalexin is the safe default.
• Emphysematous pyelonephritis = uncontrolled diabetes until proven otherwise; gas in the parenchyma on CT demands urgent drainage.